You are here: Industry Insights > Astellas

News List

Astellas Pharma acquires Quethera for $108.5m pharmaceutical-technology
August 15, 2018
Japan-based Astellas Pharma has acquired British gene therapy company Quethera, which primarily develops new treatments for ocular diseases such as glaucoma.
Astellas acquires gene therapy group Quethera in £85 million deal pharmafile
August 14, 2018
The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million.
Astellas acquires Quethera for up to £85M biospectrumasia
August 13, 2018
Through this transaction, Astellas has acquired Quethera's ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatment of glaucoma.
Astellas absorbs U.K. ocular gene therapy player Quethera fiercebiotech
August 13, 2018
Japan’s Astellas Pharma has delved deeper into the gene therapy sector, picking up U.K. specialist Quethera for around $109 million.
Q2 results roundup - 27 July pharmatimes
July 30, 2018
Amgen has posted higher sales in Q2 2018 boosted by double-dgitig growth from some of its recently launched products. Revenue rose by 4% to $6.1 billion, above forecasts $5.7 billion. CEO Robert Bradway noted that "our two most recently launched products,
With FDA nod, Pfizer and Astellas’ Xtandi gets its shot at blockbuster sales boost fiercepharma
July 17, 2018
Pfizer and Astellas have their chance to bring Xtandi to prostate cancer patients before their disease has spread through the body.
FDA expands Pfizer and Astellas' Xtandi into castration-resistant prostate cancer pharmafile
July 17, 2018
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand its label indications to include the treatment of metastatic castration-resistant prostate cancer (CRPC).
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel firstwordpharma
July 10, 2018
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and
Priority review for Astellas’ AML drug pharmatimes
June 06, 2018
Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.
Astellas cuts 600 positions in Japan as new CEO makes his mark fiercepharma
May 28, 2018
Joining a host of other drug companies announcing slim-down efforts in recent months, Astellas is shedding 600 positions in Japan in R&D and sales and marketing.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page